Sean Lee
Stock Analyst at HC Wainwright & Co.
(1.45)
# 1738
Out of 5,218 analysts
92
Total ratings
41.82%
Success rate
16.33%
Average return
Main Sectors:
Top Industries:
| Name | Action | Price Target | Current | % Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
Plus Therapeutics | Reiterates: Buy | 8 | 1.25 | 540% | 10 | Nov 26, 2024 | |
Myomo | Reiterates: Buy | 8 8 | 6.24 | 20.19% | 4 | Nov 13, 2024 | |
Monopar Therapeutics | Maintains: Strong Buy | 6 22 | 25.34 | -13.18% | 8 | Nov 11, 2024 | |
CytoSorbents | Reiterates: Neutral | 1 1 | 1.06 | -5.66% | 11 | Nov 11, 2024 | |
Alphatec Holdings | Reiterates: Buy | 20 20 | 9.63 | 107.68% | 10 | Oct 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Buy | 7 7 | 4.49 | 55.9% | 11 | Oct 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Neutral | 1 5 | n/a | n/a | 4 | Oct 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Neutral | 4 1 | n/a | n/a | 14 | Oct 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Buy | 20 20 | 3.55 | 463.38% | 4 | Jul 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Buy | 12 6 | 3.23 | 85.76% | 7 | May 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Buy | 5 | n/a | n/a | 7 | Nov 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Buy | 30 | 1 | 2900% | 1 | Dec 5, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Neutral | n/a | n/a | n/a | 1 | Mar 19, 2021 |